Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1997 1
1998 1
2003 1
2005 1
2007 2
2009 1
2011 1
2012 1
2013 2
2014 1
2015 1
2016 3
2017 4
2018 3
2019 1
2020 1
2021 3
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
AGA Clinical Practice Update: Coagulation in Cirrhosis.
O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. O'Leary JG, et al. Gastroenterology. 2019 Jul;157(1):34-43.e1. doi: 10.1053/j.gastro.2019.03.070. Epub 2019 Apr 12. Gastroenterology. 2019. PMID: 30986390 Review.
BEST PRACTICE ADVICE 4: The following transfusion thresholds for management of active bleeding or high-risk procedures may optimize clot formation in advanced liver disease: hematocrit 25%, platelet count >50,000, and fibrinogen >120 mg/dL. ...Neither is belie …
BEST PRACTICE ADVICE 4: The following transfusion thresholds for management of active bleeding or high-risk procedures may optimize clot for …
Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
Ay C, Pabinger I, Cohen AT. Ay C, et al. Thromb Haemost. 2017 Jan 26;117(2):219-230. doi: 10.1160/TH16-08-0615. Epub 2016 Nov 24. Thromb Haemost. 2017. PMID: 27882374 Review.
In this review, we discuss the epidemiology and burden of the disease, the pathophysiology of cancer-associated VTE, and the clinical treatment options for both primary prevention and acute treatment. ...Furthermore, blood count parameters (e.g. platelets …
In this review, we discuss the epidemiology and burden of the disease, the pathophysiology of cancer-associated VTE, and the clinical …
The Pathophysiology and Management of Acute Traumatic Coagulopathy.
Duan K, Yu W, Li N. Duan K, et al. Clin Appl Thromb Hemost. 2015 Oct;21(7):645-52. doi: 10.1177/1076029613516190. Epub 2013 Dec 19. Clin Appl Thromb Hemost. 2015. PMID: 24363215 Free article. Review.
To date, the possible mechanisms include activation of protein C, shedding of endothelial glycocalyx, catecholamine release, platelet dysfunction, primary, and secondary fibrinolysis, with tissue injury and hypoperfusion as the triggers. ...
To date, the possible mechanisms include activation of protein C, shedding of endothelial glycocalyx, catecholamine release, plate …
Advances in diagnosis and treatment of eosinophilia.
Sheikh J, Weller PF. Sheikh J, et al. Curr Opin Hematol. 2009 Jan;16(1):3-8. doi: 10.1097/MOH.0b013e32831c841f. Curr Opin Hematol. 2009. PMID: 19057198 Free PMC article. Review.
PURPOSE OF REVIEW: Hypereosinophilic syndromes (HESs) are disorders characterized by sustained blood or tissue hypereosinophilia or both with subsequent damage to various organs due to eosinophilic infiltration and release of mediators. ...SUMMARY: The contem …
PURPOSE OF REVIEW: Hypereosinophilic syndromes (HESs) are disorders characterized by sustained blood or tissue hypereosinophil …
The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.
Rosińska J, Łukasik M, Kozubski W. Rosińska J, et al. Cardiovasc Drugs Ther. 2017 Dec;31(5-6):627-644. doi: 10.1007/s10557-017-6757-7. Cardiovasc Drugs Ther. 2017. PMID: 29164426 Free PMC article. Review.
Platelet-derived microvesicles (pMVs) are small, heterogeneous vesicles released from platelet membranes as a result of activation. ...The purpose of this review is to discuss the effects of drugs routinely used in primary and secondary prevention of v …
Platelet-derived microvesicles (pMVs) are small, heterogeneous vesicles released from platelet membranes as a result of …
Treatment and prevention of necrotizing enterocolitis.
Lee JS, Polin RA. Lee JS, et al. Semin Neonatol. 2003 Dec;8(6):449-59. doi: 10.1016/S1084-2756(03)00123-4. Semin Neonatol. 2003. PMID: 15001117 Free PMC article. Review.
Intestinal ischaemia is likely to be the final common pathway in NEC; however, it is due to the release of vasoconstricting substances, such as platelet activating factor, rather than perinatal asphyxia. ...Infants with perforation are generally operated upon; howev …
Intestinal ischaemia is likely to be the final common pathway in NEC; however, it is due to the release of vasoconstricting substance …
Pathogenesis and management of idiopathic myelofibrosis.
Reilly JT. Reilly JT. Baillieres Clin Haematol. 1998 Dec;11(4):751-67. doi: 10.1016/s0950-3536(98)80037-1. Baillieres Clin Haematol. 1998. PMID: 10640215 Review.
Idiopathic myelofibrosis is the least common and carries the worst prognosis of the chronic myeloproliferative disorders. The primary disease process is a clonal haematopoietic stem cell disorder which results in a chronic myeloproliferation and an aty …
Idiopathic myelofibrosis is the least common and carries the worst prognosis of the chronic myeloproliferative disorders. The prim …
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review.
Warkentin TE, Pai M, Linkins LA. Warkentin TE, et al. Blood. 2017 Aug 31;130(9):1104-1113. doi: 10.1182/blood-2017-04-778993. Epub 2017 Jun 23. Blood. 2017. PMID: 28646118 Free article. Review.
We also performed a literature review of HIT treatment using DOACs (rivaroxaban, apixaban, dabigatran, edoxaban). We focused on patients who received DOAC therapy for acute HIT as either primary therapy (group A) or secondary therapy (group B; initial …
We also performed a literature review of HIT treatment using DOACs (rivaroxaban, apixaban, dabigatran, edoxaban). We focused on patients who …
Coagulopathy management in liver transplantation.
Sabate A, Dalmau A, Koo M, Aparicio I, Costa M, Contreras L. Sabate A, et al. Transplant Proc. 2012 Jul-Aug;44(6):1523-5. doi: 10.1016/j.transproceed.2012.05.004. Transplant Proc. 2012. PMID: 22841202 Review.
Corrections of hematologic disturbances by administration of large volumes of crystalloid, colloid, or blood products may worsen the coagulopathy. Also, impaired clearance of fibrinolytic enzymes released from damaged cells can lead to primary fibrinolysis. . …
Corrections of hematologic disturbances by administration of large volumes of crystalloid, colloid, or blood products may worsen the …
Underutilization of medical management of peripheral artery disease among patients with claudication undergoing lower extremity bypass.
Howard R, Albright J, Powell C, Osborne N, Corriere M, Laveroni E, Sukul D, Goodney P, Henke P. Howard R, et al. J Vasc Surg. 2022 Oct;76(4):1037-1044.e2. doi: 10.1016/j.jvs.2022.05.016. Epub 2022 Jun 14. J Vasc Surg. 2022. PMID: 35709853 Free article.
OBJECTIVE: First-line treatment of peripheral artery disease (PAD) involves medical therapy and lifestyle modification. ...The primary exposure was optimal medical therapy, defined as an antiplatelet agent, a statin, and an angiotensin-converting enzym …
OBJECTIVE: First-line treatment of peripheral artery disease (PAD) involves medical therapy and lifestyle modification. ...The …
29 results